Beruflich Dokumente
Kultur Dokumente
3Q2017
Stereotaxis
at a Glance
Extensive Presence
300+ Physicians | 100+ Active Systems | 31 Countries
Attractive Market
$4B+ Existing Market | 10-15% Annual Growth | No Robotic Competitor
Financial Highlights
$32m Sales | 82% Recurring Revenue | 77% Gross Margin *2016
2 Confidential
Surgical Progress
Technological innovation has enabled various procedures to progress to less invasive surgery.
This progress shifts clinical practice but more importantly causes a significant overall increase
in the number of patients treated as reduced surgical risk and invasiveness increases access to therapy.
3 Confidential
Endovascular
Surgery
TraditionalEndovascularSurgeryisWidelyUtilizedAcrossBroadClinicalApplications. butwithInherentLimitations.
Partial List of Multi-Billion Dollar
Endovascular Surgery Markets: Mechanism of Action Catheter Design
Clot Aspiration/Retrieval
& Endovascular Coils Manipulation of the tip of the In order to allow for the transfer of
catheter is accomplished in an force along its length, catheters
indirect inelegant fashion. Force is must be designed with rigid shafts
transferred from the physicians and internal pull wires.
Transcatheter Valves fingers/hands to the base of the
catheter and then over the entire
length of the catheter.
Cardiac Ablation
Reliance on X-Ray Difficult & Complex
4 Confidential
Robotics in Surgery
Thelastdecadehasseendramaticadoptionofrobotictechnologiesthataddressthelimitationsofopenandlaparoscopicsurgery.
Twoobservations:
Roboticscapturedsignificantmarketsharedespitealackofmaterialclinicalsuperioritydata
RoboticsprovidesforDemocratizationofSkill:moresurgeonsenabledtoperformmoreproceduresmoreeffectively
Butthefieldofrobotictechnologiesforendovascularapplicationsissparse
5 Confidential
Endovascular Robotics
Mechanisms of Action
Comments
Relatively simple and inexpensive system can Increased navigational capabilities compared Control of a catheter directly at the tip allows
be used with existing catheters. Does not with traditional catheter. More rigid catheter for unmatched catheter precision, reach and
address the inherent limitations or expand the and increased size raises safety concerns. stability. Removal of pull-wires and shaft
capabilities of traditional catheters. rigidity creates a very safe catheter.
The pull mechanism of action is the most elegant in allowing for the
design and control of catheters in ways otherwise unachievable.
Stereotaxis is the only company that has developed a functional pull robotic system. The
system is robust with significant validation in >100,000 procedures at >100 hospitals.
The benefits of robotics can be combined in a synergistic and additive fashion with the
advances in mapping and manual ablation tip technology.
6 Confidential
Cardiac Ablation
Market
Annualsalesofablationandmappingproductsused Consistent,longterm,robustgrowthdrivenbyclinical
incatheterbasedablationprocedures evidence,agingpopulationandimprovedtechnology
7 Confidential
Setup of
Robotic Ablation
8 Confidential
Current Benefits of
Robotic Ablation
9 Confidential
Global Commercial
Presence
>9,000 Procedures Annually at >100 Hospitals by >300 Physicians
Europe
North America
Asia Pacific
10 Confidential
Leadership in
Complex Procedures
11 Confidential
Automation
Stereotaxis currently has functional automation software designed into its system. The
software allows for automated movement of the catheter to specific points, along defined
paths, and in preprogrammed motions. A plan is in place to methodically improve the
software towards reliable, reproducible and rapid automation. This would allow rapid
mapping using software as a replacement for expensive mapping catheters. It would also
allow efficient ablation in both the atrium and ventricle in a patient-specific
individualized fashion. Automation will be transformational for the EP field by enabling
physicians to focus on the planning and design of treatment rather than the physical
manipulation of a catheter. Only a robotic platform can allow for automation.
12 Confidential
Cardiac Ablation
Market Outlook
Convergence & Differentiation
While the cardiac ablation market is highly attractive, the Robotics has a differentiated mechanism of action providing
challenge for companies operating in it over the coming additive clinical benefits to patients and physicians when
years will be maintaining differentiation and avoiding combined with manual technologies. Stereotaxis is the only
commoditization. robotic EP company and significant barriers to entry exist.
The convergence of features is characterized by: The advances in manual technologies do not address four
Ablation Catheters - the development of balloon-based key ways robotics provides meaningful differentiation:
technologies for rapid pulmonary vein isolation, high- Safety - Unmatched safety for patients and physicians.
flow and contact force sensing capability in single point Gentle catheter significantly reduces perforation risk.
catheters, and tools for lesion prediction and assessment. Reduced radiation exposure to patients and physicians.
Mapping Systems - localization is being performed Reduced orthopedic injury to physicians.
using electric fields as well as an imbedded sensor, and Catheter Precision & Reach - Navigation of catheter
more rapid and detailed anatomic and electrical mapping from the tip allows precise access to difficult to reach
is being pursued using multi-electrode catheters. anatomies, enabling otherwise impossible procedures.
Catheter Stability - Magnetic catheter maintains contact
with beating heart tissue at consistent force ensuring
effective lesions and maintained contact.
Automation - Robotics is the only technology that will
enable full automation of procedures, allowing
physicians to focus on designing and planning
individualized therapy of patients rather than mechanics
of catheter manipulation.
13 Confidential
Primary Focus
Sales &
Customer
Related
R&D Robust innovation plan across key aspects of robotic cardiac ablation
&
BusDev Planting initial seeds for potential broader applications
14 Confidential
Innovation Plan
3GuidingGoals:
1 2 3
Patient Physician Technology
Care Choice Availability
5CoreTechnologiesinRoboticAblationProcedure:
Navigation Software X-Ray Fluoroscopy Robotic System Ablation Catheter Mapping System
15 Confidential
Financial Summary
& Commentary
Revenue Profitability
Robust and High Margin: >$30m annual revenue at >75% GM% Low Cash Utilization
Recurring Revenue: ~85% of revenue is recurring at >80% GM% ~$700,000 negative free cash flow in 2Q17
Clean Balance Sheet: $5.0m cash and no debt at 6/30/2017 Financial Strength/Depth & Medical Device Experience/Expertise
DAFNA Capital, Mr. Joe Kiani, and limited partners of DAFNA
Clean Liability Profile own majority of Stereotaxis following $24m investment late 2016
No lawsuits. Top-tier service providers and clean financial, DAFNA Capital - $200 million assets managed, 18+ year track
regulatory, and compliance history. No IP disputes. record, focus on life sciences, >21% annualized net return
Mr. Joe Kiani - Founder, CEO, Chairman and largest shareholder
Guaranteed Future Revenue at High Margin of Masimo, global leader in noninvasive patient monitoring. $4.5B
Multi-year service contracts provide assured future revenue/income valuation, ~$350m net cash, >$700m sales, >$150m profit
Alignment of Interest
CEO and Board Members are majority shareholders of Stereotaxis
16 Confidential